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Isolated proximal anomalous connections of the coronary arteries
(ANOCOR) are rare and sometimes raise diagnostic and therapeutic problems.
The prognosis depends mainly on the initial course of the ectopic vessel. In
the current guidelines, surgical repair is recommanded for high risk
ANOCOR. The lack of controlled studies and scarcity of data concerning the
long-term evaluation of ANOCOR corrected or not may explain the discor-
dance noticed between recommandations and practices. Large-scale prospec-
tive multicenter registries dedicated to ANOCOR are needed to achieve a
better understanding of the clinical profile and the impact of correction on the
natural history of these congenital coronary abnormalities.
The ANOCOR study began 31st January, 2010 with an inclusion period of
3 years. More than 450 young people (≥15-year-old) and adults have been included
by 71 interventional cardiologists from the Interventional Working Group (GACI)
of the French Society of Cardiology. A 5-years follow-up was scheduled.
Clinical characteristics, angiographic patterns and computed tomography
images, as well as the initial management of the ANOCOR cohort patients
will be presented. 
0378
Stents in pediatric and adult congenital cardiac catheterization in
France in 2013
Sébastien Hascoët (1), Zakaria Jalal (2), Alban Baruteau (3), Lucia Mauri (4),
Hélène Bouvaist (5), Ali Houeijeh (6), Aurelie Chalard (7), Ivan
Bouzguenda (8), Jean René Lusson (7), Philippe Acar (9), Jean Francois
Piéchaud (8), Jean Benoit Thambo (2), Jean Francois Godart (6), Alain
Fraisse (4)
(1) CHU Toulouse, Hôpital des enfants, Pediatric cardiac surgery, Tou-
louse, France – (2) CHU Bordeaux-M3C, Pediatric and congenital car-
diology, Bordeaux, France – (3) Centre Chirurgical Marie Lannelongue,
Pediatric cardiac surgery, Plessis Robinson, France – (4) CHU La
Timone-APHM, Pediatric cardiology, Marseille, France – (5) Clinique
Universitaire de Cardiologie – M3C, Pôle thorax et vaisseaux, Grenoble,
France – (6) CHRU Lille – M3C, Pediatric cardiology, Lille, France –
(7) CHU Clermont Ferrand – M3C, Pediatric cardiology, Clermont
Ferrand, France – (8) Institut Jacques Cartier, Pediatric cardiology,
Massy, France – (9) CHU Toulouse, Hôpital des enfants, Pediatric car-
diology, Toulouse, France
Stents have contributed to the development of the interventional catheter-
ization of congenital heart diseases (CHD). The aim of this study was to
describe current indications and results.
Methods: Participation to this study was proposed to all catheterization
laboratories specialized in CHD in France (M3C network). All cases with
stents implantation in 2013 in pediatric and adult CHD were retrospectively
included. Adverse events were assessed using the Bergersen classification.
Risk markers were searched using univariate and multivariate analysis. 
Results: 174 stents were implanted in 127 patients. Patients were aged
15.7±15.1 year old (min 5 day-old – max 70 year-old). Main indications were
transcatheter pulmonary valve replacement (prestenting and revalvulation;
n=29 patients, 23.0%), pulmonary artery branches angioplasty (n=34, 27.0%),
aortic coarctation or recoarctation stenting (n=37, 29.4%) and ductus arteri-
osus stenting (n=11, 8.7%). 18 Patients (14.3%) were under one-year old and
35 (27.8%) were over 18 year-old. Main pathologies were tetralogy of Fallot
and variants (ACC-CHD 8.3, n=45, 35.7%), and aortic coarctation (ACC-
CHD 9.2, n=36, 28.6%). More than one stent was implanted in 32 procedures
(24.4%, max. 5 stents). Main stents implanted were the CP stent (33.0%), EV3
LD max (22.0%), Valeo (16.2%) and valved stents (15.0%). 98.5% Proce-
dures were considered as successful. Adverse events were observed in 16.7%
procedures (stent related in 12.1% procedures). Serious adverse events were
observed in 12.9%. After uni- and multivariate adjustment, only procedure
type was related to the risk of total adverse events but not to stent related
adverse events. Age, weight, center, type of stents, genetic disorder and type
of CHD were not significantly related to the risk of adverse events.
Conclusion: Stents are used in various CHD catheterization procedures,
from infancy to adult age. Adverse events rate is significant and seems related
to the type of procedure.
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Objectives: To evaluate and compare the incidence, clinical presentations
and outcomes of right-sided infective endocarditis in patients with surgical
pulmonary conduit versus those with percutaneous pulmonary valve implanta-
tion.
Methods: All consecutive patients who received a pulmonary valve surgi-
cally or percutaneously between January 2009 and June 2013 were included
and evaluated for endocarditis. 
Results: Of the 195 conduits surgically implanted (surgical group) and 93
Melody valves percutaneously implanted (PPVI group), the person-time inci-
dence rates of endocarditis were 1.2 and 3.9 cases per 100 person-years in the
surgical and PPVI groups respectively (p=0.03). Clinical presentations, micro-
biology and outcomes were comparable in both groups. The implantation-
endocarditis time interval was much shorter in the Melody valve patients
(p=0.0065). On multivariate analysis, only a past history of endocarditis was
found to significantly correlate with endocarditis (p=0.004). Probability of sur-
vival at 12, 24 and 36 months was 99.5%, 93.8%, 93.8% in the surgical-group
and 98.9%, 96.8%, 92.3% in the Melody-group respectively (p=0.6). Event
free probability including endocarditis was comparable (p=0.1). 
Conclusion: There is a high person-time incidence of endocarditis in
patients with Melody valve when compared to surgically implanted pulmonary
valves. Clinical features and microbiology were comparable in both groups.
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